Key insights
6 takeaways · ~2 min read- 01
GSK reported total Q1 2025 sales of £7.5 billion, representing a 2% increase at actual exchange rates (AER) and 4% at constant exchange rates (CER).
See it on page 1 - 02
Specialty Medicines served as the primary growth driver, with sales rising 17% to £2.9 billion.
See it on page 1 - 03
Oncology and Respiratory, Immunology, and Inflammation segments saw significant growth, with sales increasing by 53% to £0.4 billion and 28% to £0.8 billion, respectively.
See it on page 3 - 04
HIV sales reached £1.7 billion in Q1 2025, marking a 7% increase compared to the previous period.
See it on page 3 - 05
Vaccines sales declined by 6% to £2.1 billion, largely impacted by a 7% decrease in Shingrix sales to £0.9 billion.
See it on page 6 - 06
Meningitis vaccine sales for the first quarter of 2025 totaled £0.4 billion.
See it on page 1
